

## **Corey S. Goodman, Ph.D.**

### President, Biotherapeutics and Bioinnovation Center



Corey Goodman is the President of Pfizer's Biotherapeutics and Bioinnovation Center. Corey joined Pfizer to head this newly established entrepreneurial R&D division to combine cutting-edge biology, advanced biologic technologies, and an entrepreneurial biotech-like culture to discover and develop new biotherapeutics. He is an Executive Officer of Pfizer and serves as a member of the Pfizer Executive Leadership Team.

Born in Chicago, Corey attended Stanford University as a Searle Scholar and earned his B.S. in Biology with distinction and honors. He was an NSF Fellow at the University of California Berkeley and earned his Ph.D. in Neurobiology. He was then a Helen Hay Whitney Postdoctoral Fellow at U.C. San Diego.

He was a Professor at Stanford University and U.C. Berkeley for over two decades, and is currently an Adjunct Professor at the University of California San Francisco in the Departments of Anatomy and Biochemistry. While on the faculty at Berkeley, Corey was an Investigator with the Howard Hughes Medical Institute, Evan Rauch Professor of Neuroscience, co-founder of the Wills Neuroscience Institute, and Head of the Division of Neurobiology.

Corey was elected a member of the U.S. National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, and a member of the American Philosophical Society. Among his many scientific honors are the Alan T. Waterman Award from the National Science Board, the Gairdner Foundation International Award for Achievement in Medical Sciences, the Wakeman Award, the March of Dimes Prize in Developmental Biology, and the Reeve-Irvine Research Medal.

Corey has advised numerous biotechnology companies, and co-founded two of them: Exelixis and Renovis. He served as the President and Chief Executive Officer of Renovis from 2001 until 2007 when the company's merger with Evotec was announced.

Among his many public service roles, Corey is Vice President of the McKnight Endowment Fund for Neuroscience, a member of the Health Section Governing Body for the Biotechnology Industry Organization (BIO), the California Council on Science and Technology, and the boards of BayBio and the Bay Area Science and Innovation Consortium (BASIC). He is former Chair of the National Research Council's board on Life Sciences